A key opinion leader in hematology oncology provides an overview of treatment options for patients with newly diagnosed CLL and discusses factors to consider when monitoring patients for disease relapse.
Videos
Jeff Sharman, MD, reviews the initial presentation, clinical workup, and treatment of the case of a 73-year-old woman with chronic lymphocytic leukemia and shares insight into the patient’s prognosis and risk stratification.
Rachel Wuerstein, MD, discusses the clinical implications of the results of the KAMILLA trial, which evaluates the benefit of trastuzumab emtansine in patients with HER2-positive breast cancer who have received prior anti-HER2 and chemotherapy-based treatment.
Alexander Spira, MD, PhD, FACP, director of the Virginia Cancer Specialists Research Institute, discusses the current standard of care for EGFR exon 20 insertion-mutated lung cancer.
Paul K. Paik, MD, discusses the newest data from the VISION trial of tepotinib in patients with non–small cell lung cancer and a MET exon 14 skipping mutations.
Ghassan K. Abou-Alfa, MD, MBA, shares clinical pearls and advice for the management of patients with unresectable HCC.
Gastrointestinal oncology expert, Dr Ghassan K. Abou-Alfa, discusses future directions and promising novel approaches under investigation for the treatment of unresectable HCC.
Dr Ghassan K. Abou-Alfa provides insight from the results of the REFLECT trial comparing sorafenib vs lenvatinib in patients with unresectable HCC and comments on the safety profile of lenvatinib.
An expert in gastrointestinal oncology comments on approaching first-line therapy for a patient with previously untreated, unresectable HCC and reviews key findings from the IMbrave150 trial.
Ghassan K. Abou-Alfa, MD, MBA, presents the case of a 68-year-old man with hepatocellular carcinoma (HCC) and shares his initial impressions.
Caron A. Jacobson, MD, MMSc, discusses the design of the phase 2 ZUMA-5 trial, which evaluated the efficacy of axicabtagene ciloleucel in relapsed/refractory indolent Non-Hodgkin Lymphoma.
Richard Finn, MD, professor of Medicine at the Geffen School of Medicine at the University of California Los Angeles, discusses both the recent advances and remaining unmet needs in hepatocellular carcinoma.
Hossein Borghaei, DO, shares insights regarding future directions and current unmet needs in extensive-stage small cell lung cancer. He provides advice to researchers about the importance of clinical trials in the setting of extensive-stage small cell lung cancer.
An expert oncologist, Hossein Borghaei, DO considers safety and efficacy data from the ATLANTIS study of lurbinectedin in combination with doxorubicin in relapsed/refractory small-cell lung cancer.
A thought leader in lung cancer, Hossein Borghaei, DO, reviews safety and efficacy data from the phase 2 basket trial of lurbinectedin in selected advanced solid tumors.
Hossein Borghaei, DO, reviews the second-line treatment options in the setting of extensive-stage small cell lung cancer: topotecan or lurbinectedin.
Hossein Borghaei, DO, reviews the currently accepted first-line treatment recommendation for extensive-stage small cell lung cancer: a triple combination of carboplatin, etoposide, and a checkpoint inhibitor (atezolizumab or durvalumab). He provides an overview of the IMpower and CASPIAN trials.
A thoracic oncologist, Hossein Borghaei, DO, provides an overview of the initial presentation, clinical work-up, treatment, and follow-up of a 59-year-old man with extensive-stage small cell lung cancer.
Debu Tripathy, MD, discusses the TBCRC049 study investigating the use of tucatinib, capecitabine, and trastuzumab in the cerebral spinal fluid of patients with HER2-positive breast cancer and leptomeningeal disease.
Jan Philipp Bewersdorf, MD, discusses the safety outcomes of a systematic review and meta-analysis of 43 studies investigating efficacy and safety of allogeneic hematopoietic cell transplant in 8739 patients with primary or secondary myelofibrosis.
Peter Riedell, MD, discusses the effect of time to relapse in patients with mantle cell lymphoma after frontline high-dose rituximab-based therapy and autologous hematopoietic cell transplantation.
Viktor Grünwald, MD, PhD, reviews the efficacy findings of lenvatinib combined with pembrolizumab and sunitinib for the treatment of patients with advanced renal cell carcinoma.
Tina Cascone, MD, PhD, discusses the basis for conducting the phase 3 IMpower010 study.
Mirvetuximab Soravtansine Plus Bevacizumab Yields High Responses in Platinum-Agnostic Ovarian Cancer
David M. O’Malley, MD, discusses final analysis data from the phase 1b FORWARD II trial of mirvetuximab soravtansine plus bevacizumab as treatment of patients with platinum-agnostic ovarian cancer.
Joshua K. Sabari, MD, reviews the therapies available to treat patients with EGFR exon 20-positive non–small cell lung cancer.
The panel of experts in breast cancer discuss enrollment of patients with TNBC in clinical trials, including considerations and barriers.
Experts in the field of breast cancer review the role of genetic testing in the selection of treatment for patients with TNBC.
Ruta Rao, MD, discusses practical considerations regarding the use of sacituzumab govitecan in patients with relapsed/refractory TNBC.
The panel of experts share their treatment recommendations for patients with residual disease after an incomplete response to TNBC therapy.
Pathologist David G. Hicks, MD, discusses the impact of residual disease in breast cancer treatment outcomes.